Literature DB >> 18022203

The promiscuity of the dopamine transporter: implications for the kinetic analysis of [3H]serotonin uptake in rat hippocampal and striatal synaptosomes.

Seth D Norrholm1, David B Horton, Linda P Dwoskin.   

Abstract

Evidence indicates that monoaminergic neurotransmitter transporters are promiscuous, transporting substrates other than their cognate neurotransmitters. For example, serotonin is transported by the dopamine transporter (DAT) under conditions in which serotonin transporter (SERT) activity is eliminated (e.g., pharmacological inhibition). We performed a kinetic analysis of [(3)H]serotonin uptake in rat striatal synaptosomes (expressing DAT and SERT) and hippocampal synaptosomes (expressing SERT, but not DAT). Nonspecific [(3)H]serotonin uptake was defined as the amount of uptake remaining in the presence of fluoxetine (10microM) or paroxetine (0.05microM). In hippocampal synaptosomes, K(m) and V(max) values for [(3)H]serotonin uptake did not differ whether fluoxetine or paroxetine was used to define nonspecific uptake. However, in striatal synaptosomes, both K(m) and V(max) values for [(3)H]serotonin uptake were greater when fluoxetine, rather than paroxetine, was used to define nonspecific uptake. These data suggest that, at the concentrations employed, fluoxetine inhibits serotonin uptake at both DAT and SERT, whereas paroxetine only inhibits serotonin uptake at SERT. Thus, when DAT is inhibited by GBR 12909, kinetic parameters for serotonin uptake via SERT in striatum are not different from those obtained in hippocampus. These findings have important implications regarding the analysis of monoaminergic reuptake in brain regions exhibiting heterogeneous transporter expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18022203      PMCID: PMC2245871          DOI: 10.1016/j.neuropharm.2007.10.001

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  49 in total

1.  Immunolocalization of the cocaine- and antidepressant-sensitive l-norepinephrine transporter.

Authors:  S Schroeter; S Apparsundaram; R G Wiley; L H Miner; S R Sesack; R D Blakely
Journal:  J Comp Neurol       Date:  2000-05-01       Impact factor: 3.215

2.  Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat.

Authors:  M S Mazei; C P Pluto; B Kirkbride; E A Pehek
Journal:  Brain Res       Date:  2002-05-17       Impact factor: 3.252

3.  Differential polarization of serotonin transporters in axons versus soma-dendrites: an immunogold electron microscopy study.

Authors:  J H Tao-Cheng; F C Zhou
Journal:  Neuroscience       Date:  1999       Impact factor: 3.590

4.  Serotonin uptake into dopamine neurons via dopamine transporters: a compensatory alternative.

Authors:  Feng C Zhou; Klaus-Peter Lesch; Dennis L Murphy
Journal:  Brain Res       Date:  2002-06-28       Impact factor: 3.252

5.  Corelease of dopamine and serotonin from striatal dopamine terminals.

Authors:  Fu-Ming Zhou; Yong Liang; Ramiro Salas; Lifen Zhang; Mariella De Biasi; John A Dani
Journal:  Neuron       Date:  2005-04-07       Impact factor: 17.173

6.  Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.

Authors:  M J Owens; D L Knight; C B Nemeroff
Journal:  Biol Psychiatry       Date:  2001-09-01       Impact factor: 13.382

7.  Hippocampal and striatal [(3)H]5-HT reuptake under acute stressors in two rat strains differing for their emotivity.

Authors:  C Martin; M Duclos; P Mormède; G Manier; F Chaouloff
Journal:  Neurosci Lett       Date:  2000-07-21       Impact factor: 3.046

8.  Effects of corticosterone ingestion on hippocampal [(3)H]serotonin reuptake in inbred rat strains.

Authors:  F Fernandez; V Coomans; P Mormede; F Chaouloff
Journal:  Endocr Regul       Date:  2001-09

9.  Further studies on conformationally constrained tricyclic tropane analogues and their uptake inhibition at monoamine transporter sites: synthesis of (Z)-9-(substituted arylmethylene)-7-azatricyclo[4.3.1.0(3,7)]decanes as a novel class of serotonin transporter inhibitors.

Authors:  Ao Zhang; Guochun Zhou; Alexander Hoepping; Jayanta Mukhopadhyaya; Kenneth M Johnson; Mei Zhang; Alan P Kozikowski
Journal:  J Med Chem       Date:  2002-04-25       Impact factor: 7.446

10.  The selective serotonin reuptake inhibitor citalopram induces the storage of serotonin in catecholaminergic terminals.

Authors:  Heberto Suarez-Roca; Luigi X Cubeddu
Journal:  J Pharmacol Exp Ther       Date:  2002-07       Impact factor: 4.030

View more
  12 in total

1.  Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression.

Authors:  Rebecca E Horton; Deana M Apple; W Anthony Owens; Nicole L Baganz; Sonia Cano; Nathan C Mitchell; Melissa Vitela; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Neurosci       Date:  2013-06-19       Impact factor: 6.167

2.  Dissociable roles of dopamine and serotonin transporter function in a rat model of negative urgency.

Authors:  Justin R Yates; Mahesh Darna; Cassandra D Gipson; Linda P Dwoskin; Michael T Bardo
Journal:  Behav Brain Res       Date:  2015-05-21       Impact factor: 3.332

3.  New Scaffold for Lead Compounds to Treat Methamphetamine Use Disorders.

Authors:  Na-Ra Lee; Guangrong Zheng; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  AAPS J       Date:  2018-02-09       Impact factor: 4.009

4.  Lobeline attenuates neonatal ethanol-mediated changes in hyperactivity and dopamine transporter function in the prefrontal cortex in rats.

Authors:  A M Smith; K A Wellmann; T M Lundblad; M L Carter; S Barron; L P Dwoskin
Journal:  Neuroscience       Date:  2011-11-20       Impact factor: 3.590

5.  Role of serotonin transporter function in rat orbitofrontal cortex in impulsive choice.

Authors:  Mahesh Darna; Jonathan J Chow; Justin R Yates; Richard J Charnigo; Joshua S Beckmann; Michael T Bardo; Linda P Dwoskin
Journal:  Behav Brain Res       Date:  2015-07-13       Impact factor: 3.332

6.  GZ-11608, a Vesicular Monoamine Transporter-2 Inhibitor, Decreases the Neurochemical and Behavioral Effects of Methamphetamine.

Authors:  Na-Ra Lee; Guangrong Zheng; Markos Leggas; Venumadhav Janganati; Justin R Nickell; Peter A Crooks; Michael T Bardo; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2019-08-14       Impact factor: 4.030

7.  Effect of environmental enrichment on dopamine and serotonin transporters and glutamate neurotransmission in medial prefrontal and orbitofrontal cortex.

Authors:  Mahesh Darna; Joshua S Beckmann; Cassandra D Gipson; Michael T Bardo; Linda P Dwoskin
Journal:  Brain Res       Date:  2014-12-20       Impact factor: 3.252

8.  Novel N-1,2-dihydroxypropyl analogs of lobelane inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release.

Authors:  David B Horton; Kiran B Siripurapu; Guangrong Zheng; Peter A Crooks; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2011-07-21       Impact factor: 4.030

9.  Rotating disk electrode voltammetric measurements of serotonin transporter kinetics in synaptosomes.

Authors:  Catherine E Hagan; John F Neumaier; James O Schenk
Journal:  J Neurosci Methods       Date:  2010-08-14       Impact factor: 2.390

10.  Nicotinic receptor activation increases [3H]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex.

Authors:  Jun Zhu; Subbu Apparsundaram; Linda P Dwoskin
Journal:  J Pharmacol Exp Ther       Date:  2008-12-16       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.